You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Controlled Release Polymer Structures for In Situ Chemical Oxidation of Contaminated Groundwater
SBC: AXNANO LLC Topic: NIEHSDESCRIPTION provided by applicant The EPA estimates that one out of every four Americans lives within three miles of a hazardous waste site Over brownfield sites are awaiting remediation and sites on the National Priorities List Potential Responsible Parties or the Superfund program are tasked with remediating these sites but insufficient funding and growing number of sites hav ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of An Integrated High Throughput Imaging and Image Analysis Platform for Muscle
SBC: CytoInformatics LLC Topic: NIADESCRIPTION provided by applicant There is growing awareness that weakness of muscle is a significant biomedical health issue associated with many different chronic diseases and aging There are a variety of different diseases that affect muscle including muscular dystrophy fibromyalgia cerebral palsy amyotrophic lateral sclerosis and myasthenia gravis each of which carries its own uniqu ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of Alkontrol herbal for Treating Alcohol Abuse
SBC: NATURAL PHARMACIA INTERNATIONAL, INC. Topic: NIAAADESCRIPTION provided by applicant This application for a Fast Track STTR award represents a collaboration between Natural Pharmacia International Inc NPI and McLean Hospital to initiate steps toward commercializing a isoflavone botanical product for treating alcoholism Excessive use of alcohol accounts for much of the public health burden related to alcohol use disorders including fetal a ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Painless, Bloodless And Safe Glucose Sensing System For The Pediatric Intensive Care Unit
SBC: Fluorometrix Biomedical Company Topic: NICHDDESCRIPTION provided by applicant Studies in the pediatric intensive care unit PICU have shown that hypoglycemia hyperglycemia as well as swings in blood glucose levels are strongly associated with higher morbidity and mortality However tight glucose control has not been proven as effective In fact hypoglycemia was found to be a real danger Thus there is a need for more careful study ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Innovative Mitigation of Radiation Effects in Advanced Technology Nodes
SBC: RELIABLE MICROSYSTEMS LLC Topic: DTRA16A003Establish a radiation-aware analysis capability in a commercial EDA design flow that will enable first-pass success in radiation-hardened by design (RHBD) for DoD ASICs in much the same way that existing EDA design suites ensure first pass functionality and performance success of complex ASICs destined for commercial applications. Layout-aware, calibrated single-event radiation models that captur ...
STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency -
Target Identification for Novel Small Molecule Therapeutic for Alzheimer's disease
SBC: CoPlex Therapeutics, LLC Topic: NIAABSTRACT Traditional approaches to drug development for Alzheimer s disease are becoming increasingly expensive and in many cases disappointingly unsuccessful Based on preliminary in vitro and in vivo studies we have identified a novel small molecule methyl dimethyl oxo dihydrobenzo c naphthyridine carboxylate UK that significantly decreases A production and pro in ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Rapid Development of Weapon Payloads via Additive Manufacturing
SBC: MATSYS INCORPORATED Topic: DTRA16A001MATSYS proposes to adapt emerging additive manufacturing techniques (so-called 3-D Printing) for use with reactive structural materials and demonstrate this capability to rapidly fabricate reactive case. Our concept incorporates two major manufacturing steps: 3D printing of green compacts from pure Al or Al-based reactive powder blend; and Microwave (MW) sintering of green compacts into net-shaped ...
STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency -
Self-fragmenting Structural Reactive Materials (SF-SRM) for High Combustion Efficiency
SBC: MATSYS INCORPORATED Topic: DTRA16A002MATSYS proposes to develop, test and evaluate a scalable metal-based reactive structural material that will self-fragment to micron or sub-micron scale fuel particles when subjected to explosive shock loading, resulting in significantly enhanced metal combustion efficiency. Use of reactive material casings offers the potential for several-fold increases in blast and overpressure by generating rapi ...
STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency -
Highly specific ATR inhibitors for the targeted treatment of a broad spectrum of cancers
SBC: Atrin Pharmaceuticals Topic: 103PROJECT SUMMARY Specific targeting of the Ataxia Telangiectasia and Rad related kinase ATR represents an emerging strategy to treat a broad spectrum of cancers most notably those that currently lack effective treatments Suppression of ATR selectively kills cells subjected to oncogenic stress alternative lengthening of telomeres ALT or loss of double strand break DSB repair mechanisms A ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
In vitro human model for individualized response to CFTR modulators
SBC: PROGENRA INC Topic: NHLBIDESCRIPTION provided by applicant The approval of the cystic fibrosis CF drug invocator for patients with the G D mutation validates CFTR modulators for improving clinical outcomes in CF For most CF patients with F del and other mutations however multi drug combination therapy will likely be necessary and sensitive biomarkers of augmented CFTR function in response to various agents ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health